Treatment of eosinophilic meningitis with a combination of prednisolone and mebendazole.
To study the efficacy of the combination of prednisolone and mebendazole for the treatment of eosinophilic meningitis, we conducted a pilot study among Thai patients with eosinophilic meningitis. Patients were given a two-week course of prednisolone, 60 mg/day, and mebendazole, 10 mg/kg/day. The primary observation parameter was the number of patients who still had headaches after the two-week course of treatment. Forty-one patients were enrolled in the study. Four (10%) patients still had headaches after the two-week course of treatment and the median length of time until complete disappearance of headaches was three days. Serious side effects were not detected. Treatment for two weeks with the combination regimen of prednisolone and mebendazole is safe and beneficial in relieving headaches in patients with eosinophilic meningitis.
Chotmongkol
Verajit
V
Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand. chotmongkolverajit@yahoo.com
Sawadpanitch
Kookwan
K
Sawanyawisuth
Kittisak
K
Louhawilai
Sitichoke
S
Limpawattana
Panita
P
D000082:Acetaminophen / Q000008:administration & dosage / Q000627:therapeutic use; D000293:Adolescent; D000328:Adult; D000368:Aged; D018712:Analgesics, Non-Narcotic / Q000008:administration & dosage / Q000627:therapeutic use; D017185:Angiostrongylus cantonensis / Q000187:drug effects / Q000472:pathogenicity; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000969:Antinematodal Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D004802:Eosinophilia / Q000188:drug therapy* / Q000469:parasitology; D005260:Female; D006801:Humans; D008297:Male; D008463:Mebendazole / Q000008:administration & dosage / Q000627:therapeutic use*; D008581:Meningitis / Q000188:drug therapy* / Q000469:parasitology; D008875:Middle Aged; D010865:Pilot Projects; D011239:Prednisolone / Q000008:administration & dosage / Q000627:therapeutic use*; D017206:Strongylida Infections / Q000150:complications / Q000188:drug therapy; D016896:Treatment Outcome
D018712:Analgesics, Non-Narcotic; D000893:Anti-Inflammatory Agents; D000969:Antinematodal Agents; D000082:Acetaminophen; D008463:Mebendazole; D011239:Prednisolone